President Donald Trump announced the departure of US Food and Drug Administration (FDA) chief Marty Makary. This decision follows weeks of political turmoil within the agency. Makary, during his tenure, faced criticism from various groups, including industry figures, politicians, and public health officials. He recently faced pressure from Trump regarding fruit-flavored vapes. Trump stated that Makary would “go on, and he’s going to lead a good life.” Kyle Diamantas will lead the FDA in an acting capacity. Makary, a vocal critic of the medical establishment during the COVID-19 pandemic, promised reform upon taking over the FDA. His departure, just over a year later, is met with criticism from pharmaceutical executives, tobacco lobbyists, and anti-abortion activists. Conservatives accuse Makary of delaying a review of the abortion pill Mifepristone. The Trump administration pushed for the sale of flavored e-cigarettes despite Makary's concerns. Public health leaders accused him of catering to anti-vaccine activists. Peter Lurie, president of the Centre for Science in the Public Interest, described Makary’s departure as more “chaos” at the Department of Health and Human Services (HHS). Lurie questioned the leadership of HHS with these vacancies.